Evidence map›Paper›PMID 34709513›Full record

ArticleBulletin of experimental biology and medicine2021

Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.

T M Zavarikina, S V Khokhlova, A S Tyulyandina, G N Khabas, A V Asaturova, Yu V Nosova, P K Brenner, M A Kapralova, D S Khodirev, M B Stenina

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

T M ZavarikinaN. M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia. tpalievskaya@yandex.ru.
S V KhokhlovaV. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of the Health of the Russian Federation, Moscow, Russia.
A S TyulyandinaN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
G N KhabasV. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of the Health of the Russian Federation, Moscow, Russia.
A V AsaturovaV. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of the Health of the Russian Federation, Moscow, Russia.
Yu V NosovaV. I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of the Health of the Russian Federation, Moscow, Russia.
P K BrennerN. M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
M A KapralovaN. M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
D S KhodirevFederal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Medical-Biological Agency of Russia, Moscow, Russia.
M B SteninaN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Healthcare of the Russian Federation · RUInstitute of Biochemical Physics NM Emanuel · RUMinistry of Health of the Russian Federation · RUFederal Medical-Biological Agency · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We analyzed associations of polymorphic markers of DNA repair genes (XRCC1, ERCC2), cell cycle control genes (TP53, MDM2, and CDKN1A), methylation of promoter region, and mutation 5382insC of BRCA1 gene in ovarian cancer with effectiveness of platinumbased chemotherapy assessed by the median of progression-free survival time for markers of DNA repair genes and by relapse risk for all studied markers. An increase in the median of progression-free survival time for carriers of the Gln allele (р=0.025) and Gln/Gln genotype (р=0.022) of the Gln399Arg XRCC1 was observed during the 19-months period after chemotherapy. In carriers of C/C genotype of 5382insC mutation of BRCA1 gene (n=6), no relapses were observed (р=0.035), while 17 of 49 patients without this mutation developed relapses. Of 14 patients with BRCA1 gene function inactivation due to promoter methylation or the presence of the C/C genotype of 5382insC, one relapse was observed (p=0.033). Multivariate analysis revealed an association of markers of the XRCC1, TP53, MDM2 genes, BRCA1 gene inactivation, and type of surgery with the risk of relapse during the follow-up period up to 19 months after the end of chemotherapy (р≤0.0007).

Indexed as

Adenocarcinoma, Clear CellAdultAgedAntineoplastic AgentsBiomarkers, TumorBRCA1 ProteinCarcinoma, EndometrioidCell CycleCyclin-Dependent Kinase Inhibitor p21Cystadenocarcinoma, SerousDNA RepairFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedMutationAntineoplastic AgentsBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21ERCC2 protein, humanMDM2 protein, humanNeoplasm ProteinsPlatinum CompoundsProto-Oncogene Proteins c-mdm2TP53 protein, humanTumor Suppressor Protein p53Xeroderma Pigmentosum Group D ProteinX-ray Repair Cross Complementing Protein 1XRCC1 protein, humanBRCA1 genecell cycle controlDNA repairovarian cancerplatinum-based chemotherapy

Identifiers

PMID34709513
OpenAlexW3174819279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.